Rovelizumab (anti-CD11a&CD18), 整合素抗体；α L 亚基（抗原 CD11A (p180)；淋巴细胞功能相关抗原 1；α 多肽）；整合素抗体；β 2 亚基（补体成分 3 受体 3 和 4 亚基）

抗体

罗维珠单抗 | 罗维珠单抗(抗 CD11a&CD18)

Lymphocyte function associated antigen, type 1, alpha subunit antibody | Antigen CD11A (p180), lymphocyte function associated antigen 1, alpha polypeptide antibody | Antigen CD11A antibody | CD 11a antibody | CD11 antigen-like family member A antibody | C

Liquid

Ab175649-5mg

5mg

无动物源

≥95%(SDS-PAGE&SEC-HPLC)

-80℃储存,避免反复冻融

超低温冰袋运输

Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.

Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0

No

CD11a: Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. CD18: Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin alpha-X/beta-2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin alpha-M/beta-2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin alpha-M/beta-2 is also a receptor for factor X. Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1.

人(Human)

人(Human)

ITGAL; ITGB2

339086-79-2

145.98 kDa

Unconjugated

Human IgG4

重组抗体

kappa

Protein A purified

拮抗剂

整合素抗体；α L 亚基（抗原 CD11A (p180)；淋巴细胞功能相关抗原 1；α 多肽）；整合素抗体；β 2 亚基（补体成分 3 受体 3 和 4 亚基）

Whole IgG